Drugs / TGI-6
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06374173 | Jan 2024 → Sep 2027 expected | — | Hefei TG ImmunoPharma Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TGI-6 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06374173 ↗ |
| Route | Intravenous | “TGI-6 will be administered intravenously at a dose and schedule as specified for the respective study part and cohort.” NCT06374173 ↗ |